Denali Therapeutics Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 129.16M26.68M335.66M48.66M108.46M330.53M
Gross Profit 129.16M26.68M335.66M48.66M108.46M330.53M
Operating items
Research & Development 75.70M74.46M143.18M193.38M212.62M265.35M358.73M423.88M396.44M
Selling, General & Administrative 11.73M15.68M32.35M46.48M60.33M79.06M90.47M103.35M105.44M
Other Operating Expenses 14.54M
Operating Expenses 87.43M90.14M175.53M239.86M272.94M344.41M449.21M527.23M501.88M
Operating Income -87.43M-90.14M-46.37M-213.18M62.72M-295.75M-340.74M-196.70M-487.34M
EBIT -87.43M-90.14M-46.37M-213.18M62.72M-295.75M-340.74M-196.70M-487.34M
Non-operating items
Interest & Investment Income 14.77M51.51M64.64M
Non Operating Income 0.78M1.96M10.13M15.22M9.24M4.59M14.77M51.51M
Net income details
EBT -87.43M-88.19M-36.24M-197.97M71.96M-291.16M-325.97M-145.19M-422.70M
Tax Provisions -0.35M0.82M-0.57M0.02M0.03M0.07M
Profit After Tax -86.65M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M
Income from Continuing Operations -87.43M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M
Consolidated Net Income -87.43M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M
Income towards Parent Company -87.43M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M
Net Income towards Common Stockholders -87.43M-88.19M-36.24M-197.61M71.14M-290.58M-325.99M-145.22M-422.77M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 87.98M94.43M95.29M96.03M120.98M122.13M136.68M138.20M145.22M
Shares Outstanding (Diluted Average) 92.62M95.61M112.70M121.52M125.53M137.37M164.47M
EBITDA -87.03M-88.18M-36.52M-196.62M70.54M-292.83M-330.38M-137.69M-421.40M
Tax Rate 0.00M0.00M0.00M